致癌融合转录因子的先驱因子活性证据。

Evidence of pioneer factor activity of an oncogenic fusion transcription factor.

作者信息

Sunkel Benjamin D, Wang Meng, LaHaye Stephanie, Kelly Benjamin J, Fitch James R, Barr Frederic G, White Peter, Stanton Benjamin Z

机构信息

Nationwide Children's Hospital, Center for Childhood Cancer and Blood Diseases, Columbus, OH 43205, USA.

The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH 43205, USA.

出版信息

iScience. 2021 Jul 16;24(8):102867. doi: 10.1016/j.isci.2021.102867. eCollection 2021 Aug 20.

Abstract

Recent characterizations of pioneer transcription factors provide insights into their structures and patterns of chromatin recognition associated with their roles in cell fate commitment and transformation. Intersecting with these basic science concepts, identification of pioneer factors (PFs) fused together as driver translocations in childhood cancers raises questions of whether these fusions retain the fundamental ability to invade repressed chromatin, consistent with their monomeric PF constituents. This study defines the cellular and chromatin localization of PAX3-FOXO1, an oncogenic driver of childhood rhabdomyosarcoma (RMS), derived from a fusion of PFs. To quantitatively define its chromatin-targeting functions and capacity to drive epigenetic reprogramming, we developed a ChIP-seq workflow with per-cell normalization (pc-ChIP-seq). Our quantitative localization studies address structural variation in RMS genomes and reveal insights into inactive chromatin localization of PAX3-FOXO1. Taken together, our studies are consistent with pioneer function for a driver oncoprotein in RMS, with repressed chromatin binding and nucleosome-motif targeting.

摘要

近期对先锋转录因子的表征为其结构以及与细胞命运决定和转化作用相关的染色质识别模式提供了见解。与这些基础科学概念相关的是,在儿童癌症中作为驱动易位融合在一起的先锋因子(PFs)的鉴定引发了这样的问题:这些融合体是否保留了侵入抑制染色质的基本能力,这与其单体PF成分一致。本研究定义了PAX3-FOXO1的细胞和染色质定位,PAX3-FOXO1是一种源自PF融合的儿童横纹肌肉瘤(RMS)的致癌驱动因子。为了定量定义其染色质靶向功能和驱动表观遗传重编程的能力,我们开发了一种具有单细胞标准化的ChIP-seq工作流程(pc-ChIP-seq)。我们的定量定位研究解决了RMS基因组中的结构变异问题,并揭示了PAX3-FOXO1在非活性染色质定位方面的见解。综上所述,我们的研究结果与RMS中一种驱动癌蛋白的先锋功能一致,该蛋白具有抑制染色质结合和核小体基序靶向作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6f0/8346656/b9b69280a719/fx1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索